Purification of antibody drug conjugates
Ion-exchange materials with covalently attached residues efficiently separate DAR species in ADCs, addressing inefficiencies in current purification methods by achieving high recovery and cost-effectiveness.
Patent Information
- Application Number
- JP2022500024
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-07-03
- Filing Date
- 2020-07-01
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2040-07-01
AI Technical Summary
Current methods for purifying antibody-drug conjugates (ADCs) are inefficient, leading to heterogeneous mixtures with variable drug-to-antibody ratios (DARs) and high purification costs due to low stability in high salt solutions and low binding capacity, necessitating improved separation techniques for DAR2 and DAR4 species.
The use of ion-exchange materials with covalently attached leucine or similar residues for ADC purification, enabling efficient separation of DAR species across a wide range of conditions, including high conductivities, with capacities exceeding 10 mg ADC/ml and recoveries greater than 90%, using a solvent pH gradient.
This approach effectively separates individual DAR species, achieves high recovery rates, and reduces purification costs compared to existing methods, ensuring optimal pharmacokinetics, efficacy, and tolerability of ADCs.
Smart Images

Figure 0007590400000024 
Figure 0007590400000025 
Figure 0007590400000026
Abstract
Description
[Technical field]
[0001] The present invention relates to ion-exchange separation materials having amino acid-based end groups, which are particularly suitable for the separation and purification of ADCs. [Background technology]
[0002] Antibody-drug conjugates (ADCs) are a new class of potent drugs typically specialized for cancer treatment. In these conjugates, antibody molecules are specialized for specific recognition of cancer cells, and a toxic payload carried by the antibody molecule destroys them. Examples of commercially available ADCs are Adcetris® and Kadcyla®.
[0003] These new drugs are produced by conjugating toxic molecules (payloads) to antibody molecules. This is typically achieved through controlled chemical conjugation methods with specific amino acid residues exposed on the surface of the antibody, e.g., lysine or cysteine after reduction of the cysteine bond. Both approaches result in a heterogeneous mixture of ADC species with variable drug to antibody ratios (DAR). The lysine conjugation route creates more than 100 possibilities and leads to a heterogeneous population with different DARs (0, 1, 2, 3, 4...>10). The cysteine conjugation route takes advantage of the four disulfide bridges of the antibody and leads to a population with even DARs (0, 2, 4, 6 and 8 as examples).
[0004] To minimize the heterogeneity of ADC species, site-specific conjugation methods can be used.These methods have better control over the exact number and location of payload molecules that are linked to antibody, but are challenging due to the limited amount of toxic molecules that are conjugated (for example, usually only 2) and the limited choice of conjugation sites (which may affect the efficacy of drugs).To overcome the manufacturing challenges in ADC heterogeneity, some chromatographic techniques can be used to remove undesirable low DAR and high DAR species.
[0005] Low DAR species are undesirable because they compete with antibody-drug conjugates and reduce the efficacy of the drug. Highly toxic payload-bearing DAR species (>6) are also undesirable because they have an impact on the efficiency and longevity of the drug (KJ Hamblett et al. in Clinical Cancer Research 10 (2004) 7063-7070). Further information on ADCs can be found in Rachel S. Zolot, Satarupa Basu, Ryan P. Million. Antibody-drug conjugates. Nature reviews Drug Discovery. 2013, 12: 259-260. Details of exemplary ADCs can be found in WO2011 / 139985, especially in Example 8.
[0006] Hydrophobic interaction chromatography is sometimes applied to purify ADC species after conjugation process (US15104359).Unfortunately, this method has limitations due to low ADC stability in high salt solution and low binding capacity (approximately 10mg / ml), which causes high purification cost and low purification efficiency.Therefore, there is a growing need in the industry to improve the efficiency of ADC drugs, mainly to obtain DAR2 and DAR4 species to achieve the best pharmacokinetics, efficacy, half-life and tolerability. Summary of the Invention
[0007] In conclusion, it would be advantageous to find a way to provide a robust and reliable antibody-drug conjugate purification step that can be effectively applied in a wide range of conditions, in which different DAR species are efficiently separated, which would also be beneficial for reducing purification costs.
[0008] It has been found that ion exchange materials bearing covalently attached leucine or similar residues can be used for the purification of ADCs enabling efficient DAR (drug-antibody ratio) species separation to be achieved at capacities of >10 mg ADC / ml material, in more preferred embodiments, capacities between 10-80 mg / ml. Moreover, this innovative ion exchange material can be used at high conductivities >10 mS / cm, in more preferred embodiments, conductivities between 10-40 mS / cm.
[0009] Surprisingly, it was possible to separate each individual DAR species regardless of their conjugation procedure using a solvent pH gradient. Moreover, the application of this innovative ion-exchange material guaranteed >90% product recovery, showing significant economic advantages compared to hydrophobic interaction or hydroxyapatite materials.
[0010] The present invention therefore relates to a separation material for ion exchange chromatography based on a hydroxyl-containing base matrix on the surface of which polymer chains are covalently grafted, comprising: a) the base support contains hydroxyl groups; b) the polymer chains are covalently attached to the support; c) the polymer chain comprises an amino acid end group -N(Y)-R3, wherein Y are each independently H or CH3, preferably H, and R3 is -CHCOOMR4, wherein R4 is C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, preferably isopropyl and isobutyl, very preferably isobutyl, or C1-C4 perfluoroalkyl; and M is H, Na, K, or NH4+ The present invention is directed to the separation material,
[0011] Preferably, the monomer units of the polymer chain are linked in a linear fashion and each monomer unit comprises an end group -N(Y)-R3. Preferably, the ion density is between 10 and 1200 μeq / g. In a preferred embodiment, Y is H and R4 is isopropyl and / or isobutyl. In a preferred embodiment, the hydroxyl-containing base matrix contains aliphatic hydroxyl groups.
[0012] In a preferred embodiment, the base matrix is a copolymer formed by copolymerization of at least one compound from groups a) and b), wherein a) at least one hydrophilically substituted alkyl vinyl ether of formula I [ka] In the formula, R1, R2, and R3 can be, independently of each other, H or C1-C6 alkyl, preferably H or -CH3; and R4 is a radical bearing at least one hydroxyl group; and b) at least one crosslinker according to formula II and / or III and / or IV, [ka] in which X is a divalent alkyl radical having 2 to 5 C atoms, preferably 2 or 3 C atoms, in which one or more methylene groups which are not adjacent and are not located in the immediate vicinity of N may be replaced by O, C=O, S, S=O, SO2, NH, NOH or N, and one or more H atoms of the methylene groups are, independently of one another, hydroxyl groups, C1-C6-alkyl, halogen, NH2, C5-C10-aryl, NH-(C1-C8)-alkyl, N-(C1-C8)-alkyl. 2、 may be substituted with C1-C6-alkoxy or C1-C6-alkyl-OH, and [ka] [ka] In the formulae III and IV, Y1 and Y2 are each independently C1-C10 alkyl or cycloalkyl, where one or more non-adjacent methylene groups or methylene groups not located in the immediate vicinity of N may be replaced by O, C=O, S, S=O, SO2, NH, NOH or N, and one or more H atoms of the methylene groups are independently of one another hydroxyl group, C1-C6-alkyl, halogen, NH2, C5-C10-aryl, NH-(C1-C8)-alkyl, N-(C1-C8)-alkyl. 2、 may be substituted by C1-C6-alkoxy or C1-C6-alkyl-OH, or C6-C18 aryl, where one or more H in the aryl system are, independently of one another, hydroxyl groups, C1-C6-alkyl, halogen, NH2, NH-(C1-C8)-alkyl, N-(C1-C8)-alkyl. 2、 may be substituted with C1-C6-alkoxy or C1-C6-alkyl-OH, and A is a divalent alkyl radical having 2 to 5 C atoms, preferably 2 or 3 C atoms, where one or more non-adjacent methylene groups or methylene groups not located in the immediate vicinity of an N may be replaced by O, C=O, S, S=O, SO2, NH, NOH or N, and one or more H of the methylene groups are, independently of one another, hydroxyl groups, C1-C6-alkyl, halogen, NH2, C5-C10-aryl, NH(C1-C8)alkyl, N(C1-C8)alkyl. 2、 It may be substituted with C1-C6-alkoxy or C1-C6-alkyl-OH.
[0013] R4 in formula I is typically an alkyl radical, a cycloaliphatic radical, or an aryl radical bearing at least one hydroxyl group. In a highly preferred embodiment, the matrix is formed by copolymerization of a hydrophilic substituted alkyl vinyl ether taken from the group 1,4-butanediol monovinyl ether, 1,5-pentanediol monovinyl ether, diethylene glycol monovinyl ether or cyclohexanedimethanol monovinyl ether with divinylethyleneurea (1,3-divinylimidazolin-2-one) as a crosslinker.
[0014] In a preferred embodiment, the separation material comprises a hydroxyl group-containing base matrix represented by formula V [ka] wherein R1, R2 and Y are each independently H or CH3, preferably H; R3 is -CHCOOMR 4 and In the formula, R 4 is C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, preferably isopropyl and isobutyl, very preferably isobutyl, or is C1-C4 perfluoroalkyl, and M is H, Na, K, or NH4; The copolymer can be prepared by subjecting the monomers to cerium(IV) catalyzed graft polymerization according to the procedure set forth above.
[0015] The graft polymerization is preferably carried out according to page 9, Example 8 of US Pat. No. 5,453,186.
[0016] The present invention further provides a separation material comprising a hydroxyl-containing base matrix having polymer chains covalently grafted to its surface. a) the base support material contains hydroxyl groups; b) the polymer is covalently bonded to the support via hydroxyl groups; c) the polymer comprises an amino acid end group -N(Y)-R3, wherein Y are each independently H or CH3, preferably H, and R3 is -CHCOOMR4, wherein R4 is C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, preferably isopropyl and isobutyl, very preferably isobutyl, or C1-C4 perfluoroalkyl; and M is H, Na, K, or NH4 + is The present invention is directed to the chromatographic purification and / or separation of antibody drug conjugates (ADCs) by contacting a sample containing the ADCs with said separation material, characterized in that:
[0017] In a preferred embodiment, the ADC target molecules are bound to the separation matrix at a pH between 2 and 7, and optionally washed and eluted by increasing the pH value to an alkaline pH, preferably above 9, for example between 9 and 11, preferably around 10. In a preferred embodiment, the sample is applied to the separation matrix at an ion density between 10 and 1200 μeq / g. In a preferred embodiment, between 10 mg and 100 mg of ADC is bound per ml of separation material. [Brief description of the drawings]
[0018] [Figure 1] FIG. 1 shows a schematic diagram of a separation material according to the present invention with a substrate (dot) functionalized with a linear polymer constructed by polymerization of acryloylleucine monomers. [Diagram 2] FIG. 2 shows a schematic diagram of a separation material according to the present invention with a substrate (dot) functionalized with a linear polymer constructed by polymerization of acryloylvaline monomers. [Diagram 3] FIG. 3 shows the reaction scheme for valine and leucine with acrylic acid chloride.
[0019] [Figure 4] Figure 4 shows the elution peaks of ADC bound on the separation matrix at 10 mg ADC / ml CV load and 250 mM NaCl. The UV adsorption signal trace is the solid line and the pH signal trace is the dashed line. [Diagram 5] FIG. 5 shows a qualitative example of elution of antibody drug conjugate species using a linear gradient of decreasing conductivity and increasing amount of 2-propanol on an analytical HPLC column (mAbPac HIC-Butyl 5 μm, 4.6×100 mm (P / N: 088558) von Thermo Fisher Scientific). Buffer A consists of 1.5 M ammonium sulfate, 0.05 M phosphate pH 7.0 and 5% 2-propanol, and buffer B consists of 0.05 M phosphate pH 7.0 and 20% 2-propanol. The HPLC column is operated at a flow rate of 1 ml / min and the gradient from buffer A to buffer B is achieved in 20 min. ADC samples are diluted in buffer A at a concentration of 5 mg / ml and 10 μl is injected onto the HPLC prior to gradient elution.
[0020] [Figure 6]FIG. 6 shows the analytical results of the sample fraction characterization displayed as quantitative area of the analyzed elution fractions (5A1-5B7) containing 10 mg ADC / ml CV load and ADC loaded (load) at 250 mM NaCl. [Figure 7] Figure 7 shows the elution peaks of ADC bound on the separation matrix at 30 mg ADC / ml CV load and 250 mM NaCl. The UV adsorption signal trace is the solid line and the pH signal trace is the dashed line. [Figure 8] FIG. 8 depicts analytical results of sample fraction characterization displayed as quantified area for analyzed elution fractions (5A2-5C6) encompassing 30 mg ADC / ml CV load and ADC loaded (Load) at 250 mM NaCl.
[0021] [Figure 9] 9 shows the deconvoluted mass spectrum for the Adcetris® sample showing the distribution of DAR species ranging from DAR0 to DAR4. The DAR6 species is undetectable due to poor ionization and method overloading of the lower DAR species. [Figure 10] Figure 10 shows the deconvoluted mass spectrum for elution fraction 5A7, which represents the maximum of the first elution peak. The molecular weight obtained is that of the DAR2 species, with no apparent presence of other DAR species.
[0022] [Figure 11] Figure 11 shows the deconvoluted mass spectrum for elution fraction 5B4, which represents the maximum of the second elution peak. The molecular weight obtained is that of the DAR4 species, with no apparent presence of other DAR species. [Figure 12] Figure 12 shows the deconvoluted mass spectrum for elution fraction 5B11, which represents the maximum of the third elution peak. The molecular weights obtained are for the DAR4 and DAR6 species. The signal intensities are not quantitative.
[0023] [Figure 13] 13 depicts the elution peak of ADC bound on the separation matrix at 60 mg ADC / ml CV load and 250 mM NaCl. The UV adsorption signal trace is the solid line and the pH signal trace is the dashed line. [Figure 14] FIG. 14 shows the analytical results of the sample fraction characterization displayed as quantified area for the elution fractions analyzed (1A1-3G12) encompassing 60 mg ADC / ml CV load and ADC loaded (Load) at 250 mM NaCl. [Figure 15] 15 shows the elution peak of bound ADC at 30 mg ADC / ml CV load and 250 mM NaCl using Capto™ MMC ImpRes chromatography resin. The UV adsorption signal trace is the solid line and the pH signal trace is the dashed line.
[0024] [Figure 16] FIG. 16 depicts analytical results of sample fraction characterization displayed as quantified area for analyzed elution fractions (4A3-2C2) encompassing 30 mg ADC / ml CV load and ADC loaded (Load) at 250 mM NaCl. [Figure 17] 17 shows the elution peaks of ADC bound on the separation matrix at 10 mg ADC / ml CV load and 50 mM NaCl. The UV adsorption signal trace is the solid line and the pH signal trace is the dashed line. [Figure 18] 18 shows the elution peaks of ADC bound on the separation matrix at 10 mg ADC / ml CV load and 100 mM NaCl. The UV adsorption signal trace is the solid line and the pH signal trace is the dashed line.
[0025] [Figure 19] 19 shows the elution peaks of ADC bound on the separation matrix at 10 mg ADC / ml CV load and 150 mM NaCl. The UV adsorption signal trace is the solid line and the pH signal trace is the dashed line. [Figure 20] Figure 20 shows the elution peaks of ADC bound on the separation matrix at 10 mg ADC / ml CV load and 200 mM NaCl. The UV adsorption signal trace is the solid line and the pH signal trace is the dashed line. [Figure 21] Figure 21 shows the elution peaks of ADC bound on the separation matrix at 10 mg ADC / ml CV load and 300 mM NaCl. The UV adsorption signal trace is the solid line and the pH signal trace is the dashed line.
[0026] [Figure 22] Figure 22 shows the elution peaks of ADC bound on the separation matrix at 10 mg ADC / ml CV load and 350 mM NaCl. The UV adsorption signal trace is the solid line and the pH signal trace is the dashed line. [Figure 23] 23 shows the elution peaks of ADC bound onto the separation matrix at 10 mg ADC / ml CV load and 350 mM NaCl using the step approach. The UV adsorption signal trace is the solid line and the pH signal trace is the dashed line. [Figure 24] Figure 24 shows the elution peaks of ADC bound on the separation matrix at 30 mg ADC / ml CV load and 250 mM NaCl. The UV adsorption signal trace is the solid line and the pH signal trace is the dashed line.
[0027] [Diagram 25]FIG. 25 depicts a qualitative example of elution of antibody drug conjugate species using a linear gradient of decreasing conductivity and increasing amount of 2-propanol on an analytical HPLC column (mAbPac HIC-Butyl 5 μm, 4.6×100 mm (P / N: 088558) von Thermo Fisher Scientific). Buffer A consists of 1.5 M ammonium sulfate, 0.05 M phosphate pH 7.0 and 5% 2-propanol, and buffer B consists of 0.05 M phosphate pH 7.0 and 20% 2-propanol. The HPLC column is operated at a flow rate of 1 ml / min and the gradient from buffer A to buffer B is achieved in 20 min. ADC samples are diluted in buffer A at a concentration of 5 mg / ml and 10 μl is injected onto the HPLC prior to gradient elution. [Figure 26] FIG. 26 shows the analytical results of the sample fraction characterization displayed as quantified area for the elution fractions analyzed (1A3-3C10) encompassing 10 mg ADC / ml CV load and ADC loaded (Load) at 250 mM NaCl.
[0028] [Figure 27] FIG. 27 shows the deconvoluted mass spectrum for the Kadcyla™ sample, showing the distribution of DAR species ranging from DAR0 to DAR7 species. [Figure 28] FIG. 28 shows the deconvoluted mass spectrum for a sample of elution fraction 3A4, which showed the distribution of lower DAR species. [Figure 29] FIG. 29 shows the deconvoluted mass spectrum for a sample of elution fraction 3B12, which showed a distribution of higher DAR species.
[0029] [Diagram 30] Figure 30 depicts the elution peak of ADC bound onto the separation matrix at 60 mg ADC / ml CV load and 250 mM NaCl. The UV adsorption signal trace is the solid line and the pH signal trace is the dashed line. [Diagram 31]FIG. 31 shows the analytical results of the sample fraction characterization displayed as quantified area for the elution fractions analyzed (2A1-4C10) encompassing 60 mg ADC / ml CV load and ADC loaded (Load) at 250 mM NaCl.
[0030] [Diagram 32] Figure 32 shows the elution peaks of ADC bound on Capto™ MMC ImpRes chromatography resin at 30 mg ADC / ml CV load and 250 mM NaCl. The UV adsorption signal trace is the solid line and the pH signal trace is the dashed line. [Diagram 33] FIG. 33 shows the analytical results of the sample fraction characterization displayed as quantified area for the elution fractions analyzed (2B1-5D1) encompassing 30 mg ADC / ml CV load and ADC loaded (Load) at 250 mM NaCl. [Diagram 34] Figure 34 shows the elution peaks of ADC bound onto the separation matrix at 10 mg ADC / ml CV load and 400 mM NaCl using the step approach. The UV adsorption signal trace is the solid line and the pH signal trace is the dashed line. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0031] 4 to 34 are further explained in the example. Before describing the invention in detail, it is to be understood that this invention is not limited to particular compositions or process steps, as such may vary. It should be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plurals of the referents unless the context clearly dictates otherwise. Thus, for example, a reference to a "ligand" includes a plurality of ligands, and a reference to an "antibody" includes a plurality of antibodies, etc.
[0032] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. The following terms are defined for the purposes of the invention as described herein.
[0033] As used herein, the term "target molecule" refers to any molecule, substance or compound that is to be isolated, separated or purified from one or more other components, e.g., impurities, in a sample. An example of a target molecule is an ADC. In the production and / or purification process, the target molecule is typically present in a liquid. The liquid may be water, a buffer, a non-aqueous solvent such as ethanol, or any mixture thereof. Beside the target molecule, the liquid may contain one or more impurities.
[0034] The liquid may also be referred to as a sample. The composition of the liquid may vary depending on the process steps carried out during production and / or purification. After a chromatographic step, the liquid typically contains a different solvent than before due to the eluent used in the chromatographic step. Typically, only after the very last purification step can the target molecule be dried to prepare the final dosage form.
[0035] The term "antibody" refers to a protein having the ability to specifically bind to an antigen. "Antibody" or "IgG" further refers to a polypeptide substantially encoded by an immunoglobulin gene or genes, or fragments thereof, that specifically binds to and recognizes an analyte (antigen). Recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as a myriad of immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta or epsilon, which in turn define the immunoglobulin classes IgG, IgM, IgA, IgD, and IgE, respectively.
[0036] An exemplary immunoglobulin (antibody) structural unit is composed of two pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" chain (about 50-70 kD), which are stabilized, for example, by interchain disulfide bonds. The N-terminus of each chain defines a variable region of about 100-110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) refer to these light and heavy chains, respectively.
[0037] Antibodies may be monoclonal or polyclonal and may exist in monomeric or polymeric form, such as IgM antibodies that exist in pentameric form and / or IgA antibodies that exist in monomeric, dimeric or multimeric form. Antibodies may also include multispecific antibodies (e.g., bispecific antibodies) and antibody fragments, so long as they retain or are modified to contain a ligand-specific binding domain.
[0038] The term "fragment" refers to a portion or part of an antibody or antibody chain that contains fewer amino acid residues than an intact or complete antibody or antibody chain. Fragments can be obtained through chemical or enzymatic treatment of an intact or complete antibody or antibody chain. Fragments can also be obtained by recombinant means. When produced recombinantly, fragments can be expressed alone or as part of a larger protein called a fusion protein. Exemplary fragments include Fab, Fab', F(ab')2, Fc and / or Fv fragments. Exemplary fusion proteins include Fc fusion proteins. In accordance with the present invention, fusion proteins are also encompassed by the term "antibody".
[0039] In some embodiments, the antibody is an Fc region-containing protein, such as an immunoglobulin. In some embodiments, the Fc region-containing protein is a recombinant protein that includes the Fc region of an immunoglobulin fused to another polypeptide or fragment thereof.
[0040] Exemplary polypeptides include, by way of example, renin; growth hormones, including human growth hormone and bovine growth hormone; growth hormone releasing factor; parathyroid hormone; thyroid stimulating hormone; lipoproteins; alpha-1-antitrypsin; insulin alpha chain; insulin beta chain; proinsulin; follicle stimulating hormone; calcitonin; luteinizing hormone; glucagon; clotting factors, such as factor VIIIC, factor IX, tissue factor, and von Willebrand factor; anticoagulants, such as protein C; atrial natriuretic factor; pulmonary surfactant; plasminogen activators, such as urokinase or tissue-type plasminogen activator (t-PA); bombesin; thrombin; hematopoietic growth factors; tumor necrosis factors-alpha and -beta; enkephalinase; RANTES (regulated on activation normally T-cell expressed and secreted); human macrophage inflammatory protein (MIP-1-α); serum albumin, such as human serum albumin; Müllerian inhibitory substance; relaxin α chain; relaxin β chain; prorelaxin; mouse gonadotropin-related peptide; microbial proteins, such as β-lactamase; DNase; IgE; cytotoxic T lymphocyte-associated antigen (CTLA) (e.g., CTLA-4); inhibin; activin; vascular endothelial growth factor (VEGF); hormone or growth factor receptors; protein A or D; rheumatoid factor; bone-derived neurotrophic factor (BDNF), neurotrophin-3, -4, -5, or -6 (NT-3, NT-4, NT-5, or NT-6), or neurotrophic factors such as nerve growth factors, such as NGF-β; platelet-derived growth factor (PDGF); fibroblast growth factors, such as αFGF and βFGF; epidermal growth factor (EGF); transforming growth factors (TGFs), such as TGF-alpha, and TGF-β, including TGF-β1, TGF-β2, TGF-β3, TGF-β4, or TGF-β5; insulin-like growth factors-I and -II (IGF-I and IGF-II); des(l-3)-IGF-I (brain IGF-I), insulin-like growth factor binding proteins (IGFBPs); CD proteins, such as CD3, CD4, CD8, CD19, CD20, CD34, and CD40; erythropoietin; bone morphogenetic factors; immunotoxins;Bone morphogenetic proteins (BMPs); interferons such as interferon-α, -β, and -γ; colony stimulating factors (CSFs), such as M-CSF, GM-CSF, and G-CSF; interleukins (ILs), such as IL-I through IL-IO; superoxide dismutase; T cell receptors; surface membrane proteins; decay accelerating factors; viral antigens, such as portions of the AIDS envelope; transport proteins; homing receptors; addressins; regulatory proteins; integrins, such as CDl Ia, CDl Ib, CDl Ic, CD 18, ICAM, VLA-4, and VCAM; tumor associated antigens, such as the HER2, HER3, or HER4 receptors; and fragments and / or variants of any of the above listed polypeptides.
[0041] In addition, an antibody according to the present invention is any protein or polypeptide, fragment or variant thereof, that specifically binds to any of the above listed polypeptides.
[0042] As used herein, and unless otherwise stated, the term "sample" refers to any composition or mixture containing a target molecule. A sample may be derived from a biological or other source. Biological sources include eukaryotic sources, such as animals or humans. A preferred sample is a blood or plasma sample from a mammal. A sample may also include diluents, buffers, detergents, contaminating species, and the like, that are found mixed with the target molecule. A sample may be "partially purified" (i.e., subjected to one or more purification steps, such as filtration or centrifugation steps) or may be obtained directly from an organism that produces the target molecule. A plasma sample is any sample that contains plasma or a portion of plasma.
[0043] The term "impurity" or "contaminant" as used herein refers to any foreign or undesired molecule, including biological macromolecules such as DNA, RNA, one or more host cell proteins, nucleic acids, endotoxins, lipids, impurities of synthetic origin, and one or more additives, that may be present in a sample containing a target molecule to be separated from one or more foreign or undesired molecules. The term "impurity" or "contaminant" as used herein can also be applied to certain immunoglobulins that need to be separated from the target molecule, such as immunoglobulin A and immunoglobulin M, which cause allergic reactions in patents. In addition, such impurities may include any reagents used in the steps of the production and / or purification process.
[0044] The terms "purify," "separate," or "isolate," as used interchangeably herein, refer to increasing the purity of a target molecule by separating it from a composition or sample that contains the target molecule and one or more other components, e.g., impurities. Typically, the purity of a target molecule is increased by removing (completely or partially) at least one impurity from the composition.
[0045] The term "chromatography" refers to any type of technique that separates an analyte of interest (e.g., a target molecule) from other molecules present in a mixture. Most often, the target molecule is separated from other molecules as a result of differences in the rate at which individual molecules of the mixture move through a stationary medium or matrix under the influence of a mobile phase or in a bind-elute process. Examples of chromatographic separation processes are reversed-phase chromatography, ion-exchange chromatography, size-exclusion chromatography, affinity chromatography, hydrophobic interaction chromatography, and mixed-mode chromatography.
[0046] A "buffer" is a solution that resists changes in pH due to the action of its acid-base conjugate components. For example, various buffers that can be used depending on the desired pH of the buffer are described in Buffers. A Guide for the Preparation and Use of Buffers in Biological Systems, Gueffroy, D., ed. Calbiochem Corporation (1975). Non-limiting examples of buffers include MES, MOPS, MOPSO, Tris, HEPES, phosphate, acetate, citrate, succinate, glycine and ammonium buffers, and combinations thereof.
[0047] The terms "matrix," "chromatography matrix," or "separation matrix" are used interchangeably herein and refer to any type of adsorbent, support, resin, or solid phase that is used as a stationary phase in a separation process to separate a target molecule (e.g., an Fc region-containing protein such as an immunoglobulin) from other molecules present in a mixture. Often, the target molecule is separated from other molecules as a result of differences in the rates at which individual molecules of the mixture move through and interact with the matrix under the influence of a mobile phase or in a bind-elute process.
[0048] The matrix, typically composed of resin particles, monolithic sorbents or membranes, can be contained in a column or cartridge. Typically, the matrix bears one or more types of ligand, meaning that the matrix comprises a base matrix or substrate to which one or more types of ligand are attached.
[0049] A "ligand" is or contains a functional group that is attached to a chromatographic base matrix and determines or influences the binding properties of the matrix. Preferably, the ligand is a polymer chain bearing one or more, preferably multiple, functional groups. Most preferred are ligands made of polymer chains bearing at least one functional group per monomer unit that builds them.
[0050] Examples of "ligands" include, but are not limited to, ion-exchange groups, hydrophobic interaction groups, hydrophilic interaction groups, thiophilic interaction groups, metal affinity groups, affinity groups, bioaffinity groups, and mixed mode groups (combinations of the foregoing). Preferred ligands that can be used herein include, but are not limited to, weak ion-exchange groups such as carboxylic acids.
[0051] The terms "ion exchange" and "ion exchange chromatography" refer to a chromatographic process in which a target molecule (e.g., an Fc region-containing target protein) in a mixture interacts with charged compounds linked (such as by covalent attachment) to an ion exchange matrix, whereby the target molecule interacts non-specifically with compounds that are more or less charged than solute impurities or contaminants in the mixture. Impurities in the mixture elute faster or slower than the target molecule from a column of ion exchange material, or are bound to or removed from the resin relative to the target molecule.
[0052] "Ion exchange chromatography" specifically includes cation exchange, anion exchange, and mixed-mode ion exchange chromatography. Ion exchange chromatography can either bind to the target molecule (e.g., Fc region-containing target protein) followed by elution, or can primarily bind to impurities while the target molecule "flows through" the column. Preferably, the ion exchange chromatography step is performed in bind-elute mode.
[0053] The phrase "ion exchange matrix" refers to a chromatography matrix that is negatively charged (i.e., a cation exchange resin) or positively charged (i.e., an anion exchange resin). The charge may be provided by attaching one or more charged ligands to the matrix, for example by covalent linkage. Alternatively, or in addition, the charge may be an inherent property of the matrix. The term "cation exchange matrix" is used herein to refer to a chromatography matrix having one or more negatively charged ligands, such as carboxylic acid groups, attached thereto, as a negatively charged example.
[0054] When "loading" a separation column in bind-elute mode, a buffer is used to load a sample or composition containing a target molecule (e.g., an Fc region-containing target protein) and one or more impurities onto a chromatography column (e.g., an ion exchange column). The buffer has a conductivity and / or pH such that the target molecule binds to the chromatography matrix while ideally all impurities do not bind to the column and flow through the column.
[0055] A buffer is used to load a sample or composition containing a target molecule (e.g., an Fc region-containing target protein) and one or more impurities onto a chromatography column (e.g., an ion exchange column) when "loading" the separation column to allow the target molecule to "flow through." The buffer has a conductivity and / or pH such that the target molecule flows through the column without binding to the chromatography matrix, while ideally all impurities bind to the column.
[0056] When "loading" a separation column to "bind and elute" a target molecule, a buffer is used to load a sample or composition containing a target molecule (e.g., an Fc region-containing target protein) and one or more impurities onto a chromatography column (e.g., an ion exchange column). The buffer has a conductivity and / or pH such that the target molecule binds to the chromatography matrix. Separation from the one or more impurities occurs following a conductivity and / or pH such that the target molecule is washed or eluted before or after the one or more impurities. Typically, the buffer in which the sample is loaded onto the matrix is called a loading buffer or sample buffer.
[0057] The term "equilibration" refers to the use of a buffer to equilibrate a chromatography matrix prior to loading a target molecule. Typically, a loading buffer is used for equilibration. "Washing" or "washing" a chromatography matrix means passing a suitable liquid, e.g., a buffer, through or over the matrix. Typically, washing is used after loading to remove weakly bound contaminants from the matrix before eluting the target molecules and / or to remove unbound or weakly bound target molecules.
[0058] In this case, typically, the washing buffer and the loading buffer are the same.When using a virus inactivation buffer, it is used to inactivate the given existing virus before eluting the target molecule.In this case, typically, the virus inactivation buffer is different from the loading buffer because it may contain detergent / detergents or have different properties (pH / conductivity / salt and their amount).
[0059] Washing can also be used to remove contaminants from the matrix after elution of the target molecule. This is done by passing a suitable liquid, such as a buffer, through or over the matrix after elution of the target molecule. In this case, the washing buffer is typically different from the loading buffer. It may contain detergent / detergents or have different properties (pH / conductivity / salts and their amounts). The washing buffer is, for example, an acidic buffer.
[0060] "Eluting" a molecule (e.g., a polypeptide of interest such as immunoglobulin G or an impurity) from a chromatography matrix means removing the molecule therefrom. Elution can be performed directly in flow-through mode, when the target molecule is eluted with a solvent in front of the loading buffer, or by changing the solution conditions so that a buffer different from the loading buffer competes with the molecule of interest for the ligand sites on the chromatography matrix. A non-limiting example is eluting a molecule from an ion exchange matrix by changing the ionic strength of the buffer surrounding the ion exchange material so that the buffer competes with the molecule for the charged sites of the ion exchange material.
[0061] The term "mean particle size" or d50 means the average particle size distribution value at 50% of the cumulative particle size distribution. Particle size is determined by laser diffraction, preferably using a Malvern's Master Sizer. The term "average pore size" refers to the average pore size distribution value at 50% of the cumulative pore size distribution. The terms "flow-through process," "flow-through mode," and "flow-through operation," as used interchangeably herein, refer to a separation technique in which at least one target molecule (e.g., an Fc region-containing protein or an antibody) contained in a sample along with one or more impurities is intended to flow through a chromatographic matrix, which generally binds one or more impurities while the target molecule generally is unbound and elutes (i.e., flows through) from the matrix with the loading buffer.
[0062] The terms "bind and elute mode" and "bind and elute process" as used herein refer to a separation technique in which at least one target molecule (e.g., an Fc region-containing protein) contained in a sample binds to a suitable chromatographic matrix (e.g., an ion exchange chromatographic medium) and is then eluted with a buffer different from the loading buffer. "Antibody drug conjugate" or "ADC" refers to an antibody or an antigen-binding fragment thereof, and is conjugated to a drug, such as a cytotoxic agent, a cytostatic agent and / or a therapeutic agent, as further described herein below.
[0063] The term "drug" is used interchangeably with "payload" herein and refers to a compound or protein or protein fragment or other cytotoxic, growth inhibitory or imaging agent that is or will be conjugated to an antibody. Thus, in some embodiments, the drug is a small molecule. In some embodiments, the small molecule is a cytotoxic agent or imaging agent. In some embodiments, the cytotoxic agent is selected from the group consisting of anthracyclines, auristatins, dolastatins, duocarmycins, enediynes, geldanamycins, maytansines, puromycins, taxanes, vinca alkaloids, SN-38, tubulysins, hemiasterins, and stereoisomers, isosteres, analogs, or derivatives thereof.
[0064] In some embodiments, the drug is a biocompatible polymer or polypeptide. As used herein, "drug" should not be construed as being limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide with the desired biological activity. Preferably, the drug is a small molecule.
[0065] The term "drug to antibody ratio" (abbreviated as "DAR") refers to the number of drug molecules conjugated per antibody. A composition, batch, and / or formulation of multiple antibody drug conjugates may be characterized by an average DAR. The DAR and average DAR can be determined by a variety of conventional means, such as UV spectroscopy, mass spectrometry, ELISA assay, radiometric analysis, hydrophobic interaction chromatography (HIC), electrophoresis, and HPLC.
[0066] The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents the function of cells and / or causes the destruction of cells. The term is intended to include radioisotopes (e.g., At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, and radioisotopes of Lu), chemotherapeutic agents, enzymes such as nucleases and their fragments, antibiotics, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant, or animal origin (including fragments and / or variants thereof), as well as various antitumor or anticancer agents disclosed below.
[0067] Other cytotoxic agents are described below. A tumoricidal agent causes the destruction of tumor cells. A "chemotherapeutic agent" is a chemical compound useful in the treatment of cancer.
[0068] Examples of chemotherapeutic agents include alkylating agents such as thiotepa and CYTOXAN® cyclophosphamide; alkyl sulfonates such as busulfan, improsulfan, and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines, including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); delta-9-tetrahydrocannabinol (dronabinol, MARINOL®); beta-lapachone; lapachol; colchicine; betulinic acid; camptothecin (synthetic analogs topotecan (HYCAMTIN®), CPT-11 (irinotecan, CAMPTOSAR®), acetylcholine, and the like). camptothecin, including scopoletin and 9-aminocamptothecin; bryostatin; kallistatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); podophyllotoxin; podophyllic acid; teniposide; cryptophycins (especially cryptophycin 1 and cryptophycin 8); dolastatins; duocarmycins (including the synthetic analogues KW-2189 and CB1-TM1); eleutherobin; pancratistatin sarcodictyin; spongiostatins; nitrogen mustards such as chlorambucil, chlornaphazine, colofosfamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, nobembikine, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosoureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine;Enediyne antibiotics (e.g., the calicheamicins, especially calicheamicin gamma 1I and calicheamicin omega 11 (see, e.g., Agnew, Chem Intl. Ed. Engl., 33: 183-186 (1994)); the dynemicins, including dynemicin A; the esperamicins; and the neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores), aclacinomycin, actinomycin, anthramycin, azaserine, bleomycin, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycin is), dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, ADRIAMYCIN® doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcelomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, Antibiotics such as cyclosporine, olivomycin, peplomycin, potfilomycin, puromycin, queramycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, and zorubicin; antimetabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as denopterin, methotrexate, pteropterin, and trimetrexate; fludarabine, 6-mercaptopurine, and thiazolamin; Purine analogues such as mipurine and thioguanine; pyrimidine analogues such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, and floxuridine; androgens such as calsterone, dromostanolone propionate, epithiostanol, mepitiostane, and testolactone; antiadrenal agents such as aminoglutethimide, mitotane, and trilostane; folic acid supplements such as folinic acid; aceglatone; aldophosphamide glycosides; aminolevulinic acid; eniluracil; amsacrine; bestravulic acid; bisantrene;edatraxate; defofamine; demecolcine; diaziquone; elfornithine; elliptinium acetate; epothilone; etoglucide; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; rosoxantrone; 2-ethylhydrazide; procarbazine; PSK® polysaccharide complex (JHS Natural Products, Eugene, OR; razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethane; vindesine (ELDISINE®, FILDESIN®); dacarbazine; mannommustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); thiotepa; taxoids, such as TAXOL® paclitaxel (Bristol-Myers Squibb Oncology, Princeton, NJ), ABRAXANE™ cremophor-free albumin-engineered nanoparticle formulation of paclitaxel (American Pharmaceutical Partners, Schaumberg, Illinois, and TAXOTERE® docetaxel (Rhone-Poulenc Rorer, Antony, France); chlorambucil; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine (VELBAN®); platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine (ONCOVIN®); oxaliplatin; leucovobin;Vinorelbine (NAVELBINE®); Novantrone; Edatrexate; Daunomycin; Aminopterin; Ibandronate; The topoisomerase inhibitor RFS2000; Difluoromethylornithine (DMFO); Retinoids such as retinoic acid; Capecitabine (XELODA®) Pharmaceutically acceptable salts, acids or derivatives of any of the above; and combinations of two or more of the above, such as CHOP, an abbreviation for combination therapy of cyclophosphamide, doxorubicin, vincristine, and prednisolone, and FOLFOX, an abbreviation for a treatment regimen with oxaliplatin in combination with 5-FU and leucovorin (ELOXATIN™);
[0069] Also included in this definition are anti-hormonal agents, which act to regulate, reduce, block, or inhibit the effects of hormones that can promote cancer growth, and are often in the form of systemic or whole-body treatments, which may be hormones themselves.
[0070] Examples include antiestrogens and selective estrogen receptor modulators (SERMs) (e.g., including tamoxifen (including NOLVADEX® tamoxifen), EVISTA® raloxifene, droloxifene, 4-hydroxytamoxifen, trioxyfene, ketoxifene, LY117018, onapristone, and FARESTON® toremifene); antiprogesterone drugs; estrogen receptor downregulators (ERDs); agents that function to suppress or shut down the ovaries. and aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazole, aminoglutethimide, MEGASE® megestrol acetate, AROMASIN® exemestane, formestany, fadrozole, RIVISOR® vorozole, FEMARA® letrozole, and ARIMIDEX® anastrozole.Additionally, the definition of such chemotherapeutic agents includes bisphosphonates such as clodronate (e.g., BONEFOS® or OSTAC®), DIDROCAL® etidronate, NE-58095, ZOMETA® zoledronic acid / zoledronate, FOSAMAX® alendronate, AREDIA® pamidronate, SKELID® tiludronate, or ACTONEL® risedronate; and troxacitabine (a 1,3-dioxolane nucleoside cytosine analog); antisense oligonucleotides, particularly, for example, those targeting PKC-alpha, Raf, H-Ras, and epidermal growth factor receptors. those that inhibit the expression of genes in signaling pathways that contribute to abnormal cell proliferation, such as (EGF-R); vaccines such as THERATOOPE® vaccine and gene therapy vaccines (e.g., ALLOVECTIN® vaccine, LEUVECTIN® vaccine, and VAXID® vaccine); LURTOTECAN® topoisomerase 1 inhibitors; ABARELIX® rmRH; lapanitib ditosylate (ErbB-2 and EGFR dual tyrosine kinase small molecule inhibitor, also known as GW572016); and pharmaceutically acceptable salts, acids, or derivatives of any of the above.
[0071] As used herein, "growth inhibitor" refers to a compound or composition that inhibits the growth of cells, particularly TAT-expressing cancer cells, either in vitro or in vivo. Thus, a growth inhibitor can be one that significantly reduces the proportion of TAT-expressing cells in S-phase. Examples of growth inhibitors include agents that block cell cycle progression (at a point other than S-phase), such as agents that induce Gl arrest and M-phase arrest. Classical M-phase blockers include vincas (vincristine and vinblastine), taxanes, and topoisomerase II inhibitors, such as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin. Those agents that arrest Gl also extend to S-phase arrest, such as DNA alkylating agents, such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C.
[0072] Further information can be found in The Molecular Basis of Cancer, Mendelsohn and Israel, eds., Chapter 1, entitled "Cell cycle regulation, oncogenes, and antitineoplastic drugs" by Murakami et al. (WB Saunders: Philadelphia, 1995), especially page 13. The taxanes (paclitaxel and docetaxel) are anticancer drugs that are both derived from the yew tree. Docetaxel (TAXOTERE®, Rhone-Poulenc Rorer), derived from the European yew, is a semisynthetic analogue of paclitaxel (TAXOL®, Bristol-Myers Squibb). Paclitaxel and docetaxel promote the assembly of microtubules from tubulin dimers and stabilize microtubules by preventing depolymerization, which results in the inhibition of mitosis in cells.
[0073] The present invention is directed to the purification of ADC. As defined above, ADC is an antibody-conjugated drug formed by covalently binding an antibody to a toxin, typically a small molecule toxin, preferably via a linker, involving lysine coupling, heavy and light chain reductive disulfide coupling, or other coupling methods. The antibody may be any kind of antibody or antibody fragment, for example a polyclonal or monoclonal antibody, preferably a monoclonal antibody. Examples of small molecule toxins are the maytansine derivatives DM1 (N2'-deacetyl-N2'-3-mercapto-1-oxopropyl)-maytansine), DM4 (N2'-deacetyl-N2'-4)-methyl-4-mercapto-1-oxopentyl)-maytansine and its analogs, the dolphin toxin derivatives MMAE (Monomethyl Auristatin E), MMAF (Monomethyl Auristatin F) and its analogs. An exemplary linker is SMCC (4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid succinimide ester).
[0074] The present invention provides a separation material, also called a resin, that comprises a base matrix to which polymer chains are attached via double bonds. The polymer chains are made of amino acids and monomers that contain polymerizable double bonds.
[0075] The present invention further provides a method for separating ADCs with different DARs, or for removing high molecular weight species, specifically aggregates, from antibody drug conjugate (ADC) preparations, and for the separation and purification of ADCs.The present invention is useful for large-scale purification of antibody drug conjugate preparations.In certain aspects of the present invention, it is beneficial to remove ADCs with high DAR (DAR>6), which are more hydrophobic and demonstrate faster clearance, which may contribute to higher toxicity and reduce therapeutic index (Tl).
[0076] In another aspect of the invention, it is beneficial to remove ADCs with low DAR (DAR<2), which contribute little to efficacy, but provide increased amounts of unconjugated antibodies that may compete with the ADC for the target antigen, leading to lower TI. In another aspect of the invention, it is beneficial to remove ADCs with high DAR (DAR>6) and ADCs with low DAR (DAR<2). In one embodiment of the invention, the purified ADCs contain a drug loading (drug-antibody ratio, DAR) between 3.5 and 4.5, and in another embodiment, between 3 and 5.
[0077] The separation material of the present invention comprises a substrate onto which tentacle-like structures are grafted. The substrate, also called base matrix, contains reactive groups available for the graft polymerization reaction, in particular OH groups, preferably aliphatic OH groups. The substrate can thus also be prepared, for example, from organic polymers.
[0078] Organic polymers of this type can be polysaccharides such as agarose, dextran, starch, cellulose, etc., or synthetic polymers such as poly(acrylamides), poly(methacrylamides), poly(acrylates), poly(methacrylates), hydrophilically substituted poly(alkylaryl ethers), hydrophilically substituted poly(alkylvinyl ethers), poly(vinyl alcohols), poly(styrenes) and copolymers of the corresponding monomers. These organic polymers can also be preferably employed in the form of crosslinked hydrophilic networks. This also includes polymers made from styrene and divinylbenzene, which, like other hydrophobic polymers, can preferably be employed in hydrophilized form.
[0079] Alternatively, inorganic materials may be employed as substrates, such as silica, zirconium oxide, titanium dioxide, aluminum oxide, etc. It is equally possible to employ composite materials, i.e. particles which can themselves be magnetized, for example by copolymerization of magnetizable particles or magnetizable cores.
[0080] However, since the materials according to the invention should preferably withstand alkaline cleaning or regeneration, e.g. at basic pH, over extended periods of use, preference is given to the use of hydrophilic substrates which are hydrolytically stable or cannot be hydrolyzed without difficulty.
[0081] The substrate may consist of irregularly shaped or spherical particles, the particle size of which may be between 2 and 1000 μm. Preference is given to particle sizes between 3 and 300 μm. The substrate may in particular be in the form of non-porous or preferably porous particles. The pore size may be between 2 and 300 nm. Preference is given to pore sizes between 5 and 200 nm.
[0082] The substrate may equally well be in the form of a membrane, a fiber, a hollow fiber, a coating or a monolithic molding, the latter preferably being in the form of a porous three-dimensional body, for example a cylinder.
[0083] In a preferred embodiment, the substrate is a copolymer formed by copolymerization of at least one compound from groups a) and b), wherein a) at least one hydrophilically substituted alkyl vinyl ether of formula I [ka] In the formula, R1, R2, and R3 can be, independently of each other, H or C1-C6 alkyl, preferably H or -CH3; and R4 is a radical bearing at least one hydroxyl group; and b) at least one crosslinker according to formula II and / or III and / or IV, [ka] in which X is a divalent alkyl radical having 2 to 5 C atoms, preferably 2 or 3 C atoms, in which one or more methylene groups which are not adjacent and are not located in the immediate vicinity of N may be replaced by O, C=O, S, S=O, SO2, NH, NOH or N, and one or more H atoms of the methylene groups are, independently of one another, hydroxyl groups, C1-C6-alkyl, halogen, NH2, C5-C10-aryl, NH-(C1-C8)-alkyl, N-(C1-C8)-alkyl. 2、 may be substituted with C1-C6-alkoxy or C1-C6-alkyl-OH, and [ka] [ka] In the formulae III and IV, Y1 and Y2 are each independently C1-C10 alkyl or cycloalkyl, where one or more non-adjacent methylene groups or methylene groups not located in the immediate vicinity of N may be replaced by O, C=O, S, S=O, SO2, NH, NOH or N, and one or more H atoms of the methylene groups are independently of one another hydroxyl group, C1-C6-alkyl, halogen, NH2, C5-C10-aryl, NH-(C1-C8)-alkyl, N-(C1-C8)-alkyl. 2、 may be substituted by C1-C6-alkoxy or C1-C6-alkyl-OH, or C6-C18 aryl, where one or more H in the aryl system are, independently of one another, hydroxyl groups, C1-C6-alkyl, halogen, NH2, NH-(C1-C8)-alkyl, N-(C1-C8)-alkyl. 2、may be substituted with C1-C6-alkoxy or C1-C6-alkyl-OH, and A is a divalent alkyl radical having 2 to 5 C atoms, preferably 2 or 3 C atoms, where one or more non-adjacent methylene groups or methylene groups not located in the immediate vicinity of an N may be replaced by O, C=O, S, S=O, SO2, NH, NOH or N, and one or more H of the methylene groups are, independently of one another, hydroxyl groups, C1-C6-alkyl, halogen, NH2, C5-C10-aryl, NH(C1-C8)alkyl, N(C1-C8)alkyl. 2、 It may be substituted with C1-C6-alkoxy or C1-C6-alkyl-OH.
[0084] R4 in formula I is typically an alkyl radical, a cycloaliphatic radical, or an aryl radical bearing at least one hydroxyl group.
[0085] In a highly preferred embodiment, the matrix is formed by copolymerization of a hydrophilic substituted alkyl vinyl ether taken from the group 1,4-butanediol monovinyl ether, 1,5-pentanediol monovinyl ether, diethylene glycol monovinyl ether or cyclohexanedimethanol monovinyl ether with divinylethyleneurea (1,3-divinylimidazolin-2-one) as a crosslinker. An example of a suitable commercially available vinyl ether-based substrate is Eshmuno®, Merck KGaA, Germany.
[0086] wherein linear polymer chains are covalently attached to a surface of a substrate such that a separation material is produced; a) the substrate contains hydroxyl groups, preferably aliphatic; b) the polymer is covalently bonded to the substrate; c) the polymer comprises amino acid residues; d) The monomer units of a polymer are linked in a linear fashion.
[0087] The actual separation material, which comprises a substrate and doubly attached linear polymer chains, can be prepared in various ways. In the "grafting onto" method, the polymer chains must first be formed from monomers and are attached to the surface in a second step. In the "grafting from" method, the polymerization reaction is initiated on the surface and the graft polymer is built up directly from the individual monomers. Other polymerization methods that allow the attachment of the support material to the surface can also be employed.
[0088] Preference is given to the "grafting from" method, and especially to variants in which only minor by-products such as non-covalently bound polymers are formed, which must be removed by separation. Processes involving controlled free radical polymerization, such as the method of atom transfer free radical polymerization (ATRP), appear to be particularly suitable. Here, initiator groups are covalently bound to the support surface in the desired density in a first step. The initiator groups are, for example, halides bound via ester functional groups, as in 2-bromo-2-methylpropionic acid ester. The graft polymerization is carried out in the presence of copper(I) salts in a second step.
[0089] A highly preferred one-step graft polymerization reaction suitable for the production of the separation materials of the present invention can be initiated by cerium(IV) on a hydroxyl-containing support material without the need to activate the support material.
[0090] The cerium(IV)-initiated grafting is preferably carried out according to EP 0 337 144 or US 5,453,186. The chains produced are linked to the substrate via monomer units. For this purpose, the substrate according to the invention is suspended in a solution of monomers, preferably in an aqueous solution. The grafting-on of the polymeric material can be carried out in the course of conventional redox polymerization with the exclusion of oxygen. The polymerization catalyst employed is the cerium(IV) ion, since this catalyst forms free radical sites on the surface of the substrate, from which the polymerization of the monomers is initiated. The reaction is usually carried out in dilute mineral acid. To carry out the graft polymerization, the acid is employed in aqueous solution, usually at a concentration in the range of 1 to 0.00001 mol / l, preferably 0.1 to 0.001 mol / l. Particular preference is given to the use of dilute nitric acid, employed at a concentration of 0.1 to 0.001 mol / l.
[0091] For the preparation of the separation material according to the invention, the monomers are usually added in excess relative to the substrate, typically between 0.05 and 100 mol total monomer per liter of deposited polymeric material, preferably between 0.05 and 25 mol / l.
[0092] The polymerization is terminated by a termination reaction involving cerium salts. For this reason, the (average) chain length can be influenced by the concentration ratio of substrate, initiator and monomer. Furthermore, homogeneous or even mixtures of different monomers can be employed; in the latter case, graft copolymers are formed.
[0093] The monomers advantageously used for the preparation of the separation material according to the invention are of formula V [ka] This is in accordance with In the formula, R 1 , R 2 and Y are each independently H or CH3, preferably H. R 3-CHCOOMR 4 and [ka] In the formula, R 4 is C1-C4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, preferably isopropyl and isobutyl, very preferably isobutyl, or is C1-C4 perfluoroalkyl, and M is H, Na, K, or NH4 + It is.
[0094] Perfluoroalkyl means that all H atoms in the alkyl residue are replaced with F atoms. An exemplary preferred structure of formula V is [ka] In the formula, R 1 , R 2 and Y is H; R 3 -CHCOOMR 4 and In the formula, R 4 is isopropyl, and M is H; And formula Vb [ka] In the formula, R 1 , R 2 and Y is H; R 3 -CHCOOMR 4 and In the formula, R 4 is isobutyl, and M is H; It is.
[0095] Such monomers may also be described as acryloyl valine (Formula Va), acryloyl leucine (Formula Vb), acryloyl alanine, acryloyl norleucine, methacryloyl valine, methacryloyl leucine, methacryloyl alanine, methacryloyl norleucine, dimethacryloyl valine, dimethacryloyl leucine, dimethacryloyl alanine, dimethacryloyl norleucine, with acryloyl valine and acryloyl leucine being preferred, and acryloyl leucine being especially preferred.
[0096] The separation materials according to the present invention preferably contain only tentacle-like linear polymer structures grafted onto a substrate constructed from monomers according to formula V. Preferably, they contain linear polymers constructed only by one type of monomer according to formula V.
[0097] However, it is also possible that a linear polymer is constructed by copolymerization of two or more different monomers according to formula V. It is also possible that a linear polymer is constructed by copolymerization of one or more different monomers according to formula V and one or more other polymerizable monomers, such as other acrylamides, methacrylates, acrylates, methacrylates functionalized (e.g., with ionic, hydrophilic or hydrophobic groups), etc.
[0098] Exemplary structures of separation materials according to the present invention are shown in Figures 1 and 2. Figure 1 shows a substrate (dot) functionalized with a linear polymer constructed by polymerization of acryloyl leucine monomers. In addition, for clarity, the carboxy alkyl end groups of each polymer unit are shown. Figure 2 shows a substrate (dot) functionalized with a linear polymer constructed by polymerization of acryloyl valine monomers. In addition, for clarity, the carboxy alkyl end groups of each polymer unit are shown.
[0099] In preferred embodiments, the separation material of the present invention is an ion exchange material with a variety of different ion density bands ranging from 10 to 1200 μeq / g, where in more preferred embodiments the ion density bands are between 400 and 900 μeq / g. In preferred embodiments, the ion exchange material can contain ion exchange and hydrophobic functional groups, where in more preferred embodiments both functional groups are on a single surface functional unit resulting from one monomeric unit built into a polymer chain, where in most preferred embodiments the functional group is part of an amino acid residue.
[0100] The present invention is further directed to a chromatography column comprising the separation material according to the present invention described above. Chromatography columns are known to those skilled in the art. They typically comprise a cylindrical tube or cartridge filled with separation material, and a filter and / or a means for fixing the separation material in the tube or cartridge, and a connection for solvent delivery into and out of the tube. The size of the chromatography column varies depending on the application, e.g., analytical or preparative.
[0101] The materials according to the invention can also be described as substrates provided with separation effectors. They can be used for selective, partially selective or non-selective binding or adsorption of one or more target components, for separation out of the sample liquid, or for selective, partially selective or non-selective binding or adsorption of one or more secondary components, for separation of secondary components out of the matrix, for isolation, enrichment and / or depletion of biopolymers from natural sources, for isolation, enrichment and / or depletion of biopolymers from recombinant sources, for isolation, enrichment and / or depletion of proteins or polypeptides, for isolation, enrichment and / or depletion of monoclonal and polyclonal antibodies, for isolation, enrichment and / or depletion of viruses, for isolation, enrichment and / or depletion of host cell proteins, for isolation, enrichment and / or depletion of ADCs. A preferred target molecule is an ADC.
[0102] The target molecule is separated from one or more other substances from a sample, in which the sample containing the target molecule is dissolved in a liquid, which is contacted with the material according to the invention. The contact time is usually in the range of 30 seconds to 24 hours. It is advantageous to work according to the principle of liquid chromatography by passing the liquid through a chromatography column containing the separation material according to the invention. The liquid can pass through the column simply through its gravity or by being pumped through it by means of a pump.
[0103] An alternative method is batch chromatography, in which the target molecules or biopolymers are mixed with the liquid by stirring or shaking for the length of time required to allow them to bind to the separation material. In the same way, it is possible to work according to the principle of a chromatographic fluidized bed by introducing the liquid to be separated into, for example, a suspension containing a separation material, where the separation material is selected to be suitable for the desired separation due to its high density and / or magnetic core.
[0104] When the chromatographic process is operated in bind-elute mode, the target molecules bind to the separation material according to the invention. The separation material can then be washed with a washing buffer, which preferably has the same ionic strength and the same pH as the liquid in which the target molecules are contacted with the separation material. The washing buffer removes all substances that do not bind to the separation material. This may be followed by a further washing step with another suitable buffer, without desorbing the target molecules. Desorption of the bound target molecules is carried out by changing the ionic strength in the eluent and / or by changing the pH in the eluent and / or by changing the solvent. The target molecules are thus obtained in purified and concentrated form in the eluent. The target molecules usually have a purity of 70% to 99%, preferably 85% to 99%, particularly preferably 90% to 99% after desorption.
[0105] However, if the chromatographic process is operated in flow-through mode, the target molecule remains in the liquid, but other accompanying substances bind to the separation material. The target molecule is then directly obtained by collecting the column eluate in the through-flow. The skilled person knows how he has to adapt the conditions, especially pH and conductivity, to bind a particular biopolymer to the separation material, or whether it is advantageous for the purification task not to bind the target molecule.
[0106] The present invention is preferably directed to the use of a separation material according to the invention as described above for the separation and purification of ADCs, as well as to a method for the separation and / or purification of ADCs by liquid chromatography comprising contacting a separation material according to the invention with a sample comprising one or more ADCs under acidic conditions.
[0107] Unexpectedly, we have found that the ion exchange material according to the invention can be used for the purification of ADCs enabling efficient DAR (drug antibody ratio) species separation to be achieved at capacities of >10 mg ADC / ml material, in more preferred embodiments the capacity being between 10-80 mg / ml. Moreover, this innovative ion exchange material can be used at high conductivities >10 mS / cm, in more preferred embodiments the conductivity being between 10-40 mS / cm.
[0108] Surprisingly, it is possible to separate each individual DAR species, regardless of their conjugation procedure, preferably using a pH change from 4-7 to a pH above 9, preferably in gradient or step mode at a pH between 9-11, most preferably around pH 10. Moreover, the application of this separation material ensures a product recovery rate of >90%, showing significant economic advantages compared to hydrophobic interaction or hydroxyapatite materials. In addition, the application is not limited to the separation of different DAR species, but can also be used to remove unconjugated mAB. Moreover, the application of the separation material is not limited to the separation of different DAR species, but can also be used to remove unconjugated toxic molecules.
[0109] In addition, the application of this material is not limited to bind-elute applications, but can also be used in flow-through mode, resulting in the adsorption of higher DAR species onto the ion-exchange material using buffers with pH<7 and / or high conductivity (>20mS / cm). Moreover, surprisingly, only this ion-exchange material, which consists primarily of amino acids covalently attached to the material, has the required selectivity for DAR species, in a more preferred embodiment, these amino acids are valine or leucine (including combinations and derivatives thereof), and most preferred is leucine.
[0110] Furthermore, the present invention provides a chromatography-based ADC purification step that can be regenerated and is applicable over a wide operation window, e.g., pH 3-10; conductivity 1 mS / cm-50 mS / cm. In a preferred embodiment, the ion exchange material according to the present invention is incorporated into a chromatography column and used for the ADC purification process in bind-elute mode to separate the DAR species.
[0111] In a preferred embodiment, the ion exchange material according to the present invention is incorporated into a chromatography column and used for an ADC purification process in bind-elute mode to separate the DAR species, where the operation window spans between pH 2 and pH 10, in a more preferred embodiment the pH is between 4 and 7. In a preferred embodiment, the ion exchange material according to the invention is incorporated into a chromatography column and used for the ADC purification process in bind-elute mode to separate the DAR species, where a solvent pH elution is used to recover the bound components.
[0112] In a preferred embodiment, the ion exchange material according to the invention is incorporated into a chromatography column and used for an ADC purification process in bind-elute mode to separate DAR species, where the binding window spans between 10 mg ADC / ml material and 100 mg ADC / ml material, in a more preferred embodiment the binding window spans between 20 mg ADC / ml material and 80 mg ADC / ml material.
[0113] In a preferred embodiment, the ion exchange material according to the present invention is incorporated into a chromatography column and used for an ADC purification process in bind-elute mode to separate DAR species, where the conductivity band span is between 1 mS / cm and 50 mS / cm, in a more preferred embodiment the conductivity range is between 2 and 30 mS / cm.
[0114] In another preferred embodiment, an ion exchange material according to the invention is incorporated into a chromatography column and used for an ADC purification process in flow-through mode to separate DAR species, where the low DAR species are in the flow-through and the higher DAR species bind to the material.
[0115] In a preferred embodiment, the ion exchange material can be of various particle sizes ranging from 1 μm to 200 μm, and in a more preferred embodiment, the average particle size is between 20 and 63 μm. In a preferred embodiment, the ion exchange material according to the present invention can have a variety of pore sizes ranging from 4 nm to 1500 nm, in a more preferred embodiment the average pore size is between 10 and 120 nm, and in a most preferred embodiment the average pore size is between 40 and 110 nm.
[0116] The present invention is further illustrated by the following figures and examples, without, however, being limited thereto. The entire disclosures of all applications, patents, and publications cited above and below, as well as in corresponding EP Patent Application No. 19184130.3, filed July 7, 2019, are hereby incorporated by reference. EXAMPLES
[0117] example The following examples illustrate practical applications of the present invention.
[0118] 1. Synthesis of separation materials For the preparation of monomers used for grafting from the process, amino acids, e.g. valine, leucine or alanine, are dissolved in VE water and the pH is adjusted to a pH above 13 by adding NaOH (32%). An acrylic compound, such as acrylic acid chloride or acrylic acid, is added at a temperature between 0-5°C and the mixture is stirred for 1 hour. The reaction scheme for valine and leucine with acrylic acid chloride is shown in FIG.
[0119] The pH is then adjusted to about 2.2 by adding nitric acid, after which an OH-containing substrate, such as Eshmuno® particles, is added. The polymerization is initiated by adding cerium(IV) nitrate. The reaction is carried out at 30-50°C for 4 hours. After the polymerization reaction, non-reacted components and initiators are removed by extensive washing with acidic, basic and solvent mixtures at room or elevated temperatures.
[0120] For the preparation of the separation material bearing perfluoroalkylated end groups, hexafluorovaline is dissolved in VE water and the pH is adjusted to a pH above 13 by adding NaOH (32%). An acrylic compound such as acrylic acid chloride or acrylic acid is added at a temperature between 0-5°C and the mixture is stirred for 1 hour. The pH is then adjusted to about 2.2 by adding nitric acid. Afterwards, an OH-containing substrate, e.g. Eshmuno® particles, is added. Polymerization is initiated by adding cerium (IV) nitrate. The reaction is carried out at 30-50°C for 4 hours.
[0121] 2. Ion exchange material as prepared according to Example 1 (for example with average particle size between 20-63 μm, average pore size between 40-110 nm and ion density between 400-900 μeq / g) was evaluated for its ability to separate ADC species of the commercial drug Adcetris®. The ion exchange material was packed into a chromatographic column of 5×100 mm dimensions with an asymmetry between 0.8-1.2 and >3000 plates / m. After packing the ion exchange material, the resulting chromatographic column was washed with 1 M NAOH solution for 30 min and pre-equilibrated with 300 mM NaCl with a loading buffer solution having a pH of 4.5 (for example, 24 mS / cm). The buffer solution contained a combination of salts such as sodium dihydrogen phosphate, TRIS, glycine, etc. to obtain a pH of 4.5. The same solution was used to dissolve the lyophilized Adcetris® sample up to a concentration of 1 mg / ml.
[0122] The solution was loaded onto the prepared chromatographic column until a load of 10 mg Adcetris® per ml resin was reached. These steps and subsequent steps were performed at a buffer velocity of 150 cm / h. After loading 10 mg / ml Adcetris®, the chromatographic column was washed with a buffer solution of pH 4.5 and then eluted using gradient elution with a buffer having a pH of 8.5 and 300 mM NaCl. The elution buffer was prepared using different salts such as sodium dihydrogen phosphate, TRIS, glycine, etc. The conductivity and pH values were traced during the experimental setup, which shows that Adcetris® elution from the column was achieved due to pH changes during gradient elution.
[0123] The sample eluate was fractionated and the resulting fractions were evaluated in line using two different methods for DAR species identification. The first method chosen was hydrophobic interaction chromatography using a mAbPac HIC-Butyl column of 4.6 x 100 mm dimensions from Thermo Fisher Scientific. Chromatographic separation of the fractionated samples enabled us to identify the different DAR species and their quality based on the different elution windows for each species (for example, DAR0 species eluted between 7-9 min, DAR2 species eluted between 10-14 min, DAR4 species eluted between 15-18 min and DAR6 species eluted between 19-22 min).
[0124] An example chromatographic experiment with 10 mg / ml Adcetris® loading is shown in Figure 4, where the UV adsorption signal trace is a solid line and the pH signal trace is a dashed line. Fractions were collected and analyzed using analytical HIC (hydrophobic interaction chromatography) HPLC, and the amounts of different DARs were calculated using the quantitative areas (Figure 4).
[0125] Figure 5 illustrates the separation of antibody drug conjugate species during a linear elution gradient on an analytical HPLC column. Five consecutive elution pools were identified in the UV signal trace, representing five different antibody drug conjugate species: peak 1 represents the antibody drug conjugate species without drug, peak 2 represents the antibody drug conjugate species with two drug molecules conjugated to a single antibody molecule, peak 3 represents the antibody drug conjugate species with four drug molecules conjugated to a single antibody molecule, peak 4 represents a mixture of antibody drug conjugate species, and peak 5 represents the antibody drug conjugate species with six drug molecules conjugated to a single antibody molecule.
[0126] The antibody drug conjugate species identified differ in their average hydrophobicity, with some being more hydrophilic (example, left) to hydrophobic (example, right). Analytical evaluation using hydrophobic interaction chromatography of the collected fractions is displayed in FIG. 6 and shows that the three obtained peaks indicate the separation of DAR species, i.e., the first peak is mainly DAR2 and DAR6 species (as an example, with an elution maximum at 98 ml), the second peak is mainly DAR4 species (as an example, with an elution maximum at 104 ml), and the third one - DAR6 species (as an example, with an elution maximum at 125 ml).
[0127] As shown in Figure 6, separation / enrichment at different DARs is possible using linear pH gradient elution. In the first peak of Figure 1, the purity of DAR2 increased to 40% (starting level DAR2 24%). In the second peak, the purity of DAR4 increased to 65% (starting level 22%). In the third peak, the purity of DAR6 increased to 95% (starting level 37%).
[0128] 3. In this experiment, the ion exchange material prepared according to Example 1 (for example, with an average particle size between 20-63 μm, an average pore size between 40-110 nm and an ion density between 400-900 μeq / g) was evaluated for its ability to separate the ADC species of the commercial drug Adcetris®. The ion exchange material was packed into a chromatographic column of dimensions 5×100 mm with an asymmetry between 0.8-1.2 and >3000 plates / m. After packing the ion exchange material, the resulting chromatographic column was washed with 1 M NAOH solution for 30 min and pre-equilibrated with a loading buffer solution having a pH of 4.5 and 300 mM NaCl (for example, 24 mS / cm). The buffer solution contained a combination of salts such as sodium dihydrogen phosphate, TRIS, glycine, etc. to obtain a pH of 4.5. The same solution was used to dissolve the lyophilized Adcetris® sample up to a concentration of 1 mg / ml.
[0129] The solution was loaded onto the prepared chromatographic column until a loading of 30 mg Adcetris® per ml resin was reached. These steps and subsequent steps were performed at a buffer velocity of @150 cm / h. After loading 30 mg / ml Adcetris®, the chromatographic column was washed with a buffer solution of pH 4.5 and then eluted using gradient elution with a buffer having a pH of 8.5 and 300 mM NaCl. The elution buffer was prepared using different salts such as sodium dihydrogen phosphate, TRIS, glycine, etc. The conductivity and pH values were traced during the experimental setup, which shows that Adcetris® elution from the column was achieved due to pH changes during gradient elution.
[0130] The sample eluate was fractionated and the fractions obtained were evaluated in line using two different methods for DAR species identification. The first method chosen was hydrophobic interaction chromatography using a mAbPac HIC-Butyl column of 4.6 x 100 mm dimensions from Thermo Fisher Scientific. Chromatographic separation of the fractionated samples made it feasible for us to identify the different DAR species and their quality based on the different elution bands for each species (for example, DAR0 species eluted between 7-9 min, DAR2 species eluted between 10-14 min, DAR4 species eluted between 15-18 min and DAR6 species eluted between 19-22 min).
[0131] The second method chosen was mass spectrometry, where different DAR species are separated based on their mass and ionization ratio. Using this method, qualitative, but not quantitative, sample evaluation is possible due to the different ionization of DAR species (e.g., higher DAR species tend to ionize to a lower extent). An example chromatographic experiment with 30 mg / ml Adcetris® loading is shown in Figure 7, where the UV adsorption signal trace is a solid line and the pH signal trace is a dashed line.
[0132] Analytical evaluation using hydrophobic interaction chromatography of the collected fractions is displayed in FIG. 8 and shows the separation of the DAR species with three resulting peaks, the first peak being mainly DAR2 species (e.g., elution maximum @ 110 ml), the second peak being mainly DAR4 species (e.g., elution maximum @ 125 ml), and the third one - DAR6 species (e.g., elution maximum @ 140 ml).
[0133] As shown in Figure 8, separation / enrichment at different DARs is possible using linear pH gradient elution. In the first peak of Figure 7, the purity of DAR2 increased to 55% (starting level 28%). In the second peak, the purity of DAR4 increased to 81% (starting level 29%). In the third peak, the purity of DAR6 increased to 87% (starting level 26%). Selected sample fractions were further evaluated using mass spectrometry to assess the quality of the DAR species separation. The results shown in Figures 9-12 indicate that each obtained fraction contained the identified DAR species.
[0134] 9 shows a deconvoluted mass spectrum for an Adcetris® sample showing the distribution of DAR species ranging from DAR0 to DAR4. The DAR6 species is undetectable due to poor ionization and method overloading of the lower DAR species. Figure 10 shows the deconvoluted mass spectrum for elution fraction 5A7, which represents the maximum of the first elution peak. The molecular weight obtained is that of the DAR2 species, with no apparent presence of other DAR species.
[0135] Figure 11 shows the deconvoluted mass spectrum for elution fraction 5B4, which represents the maximum of the second elution peak. The molecular weight obtained is that of the DAR4 species, with no apparent presence of other DAR species. Figure 12 shows the deconvoluted mass spectrum for elution fraction 5B11, which represents the maximum of the third elution peak. The molecular weights obtained are for the DAR4 and DAR6 species. The signal intensities are not quantitative.
[0136] 4. In this experiment, the ion exchange material prepared according to Example 1 (for example, with an average particle size between 20-63 μm, an average pore size between 40-110 nm and an ion density between 400-900 μeq / g) was evaluated for its ability to separate the ADC species of the commercial drug Adcetris®. The ion exchange material was packed into a chromatographic column of dimensions 5×100 mm with an asymmetry between 0.8-1.2 and >3000 plates / m. After packing the ion exchange material, the resulting chromatographic column was washed with 1 M NAOH solution for 30 min and pre-equilibrated with a loading buffer solution having a pH of 4.5 and 300 mM NaCl (for example, 24 mS / cm). The buffer solution contained a combination of salts such as sodium dihydrogen phosphate, TRIS, glycine, etc. to obtain a pH of 4.5. The same solution was used to dissolve the lyophilized Adcetris® sample up to a concentration of 1 mg / ml.
[0137] The solution was loaded onto the prepared chromatographic column until a loading of 60mg Adcetris® per ml resin was reached. These steps and subsequent steps were performed at a buffer velocity of @150cm / h. After loading 60mg / ml Adcetris®, the chromatographic column was washed with a buffer solution of pH 4.5 and then eluted using gradient elution with a buffer having a pH of 8.5 and 300mM NaCl. The elution buffer was prepared using different salts such as sodium dihydrogen phosphate, TRIS, glycine, etc. The conductivity and pH values were traced during the experimental setup, which shows that Adcetris® elution from the column was achieved due to pH changes during gradient elution.
[0138] The sample eluate was fractionated and the fractions obtained were evaluated in line using two different methods for DAR species identification. The first method chosen was hydrophobic interaction chromatography using a mAbPac HIC-Butyl column with dimensions 4.6 x 100 mm from Thermo Fisher Scientific. Chromatographic separation of the fractionated sample enabled us to identify the different DAR species and their quality based on the different elution bands for each species (for example, DAR0 species eluted between 7-9 min, DAR2 species eluted between 10-14 min, DAR4 species eluted between 15-18 min and DAR6 species eluted between 19-22 min). An example chromatographic experiment with a 60 mg / ml Adcetris® load is shown in Figure 13, where the UV adsorption signal trace is represented by a solid line and the pH signal trace is represented by a dashed line.
[0139] Analytical evaluation using hydrophobic interaction chromatography of the collected fractions is displayed in FIG. 14, and shows the separation of the three resulting peaks into DAR species, i.e., the first peak is mainly DAR2 species (e.g., elution maximum @ 188 ml), the second peak is mainly DAR4 species (e.g., elution maximum @ 205 ml), and the third one - DAR6 species (e.g., elution maximum @ 230 ml).
[0140] Surprisingly, even at a loading of 60 mg / ml, separation of DAR species is possible, and purified DAR2 species is obtained, as seen in fraction 3B4, which contains 49.66% of DAR2 species. Moreover, fraction 3C2 contains mainly DAR4 species, which is 83.02%, and fraction 3C12 contains mainly DAR6 species, which is 83.12%. This result was obtained within a recovery rate of 97.37% for all chromatographic steps combined.
[0141] 5. In this experiment, the commercially available Capto™ MMC Impres chromatographic resin was evaluated for its ability to separate the ADC species of the commercially available drug Adcetris®. This mixed-mode material also has weak cation exchange and hydrophobic groups and was suitable for the separation of ADC species. The Capto™ MMC Impres material was packed into a chromatographic column of dimensions 5×100 mm with an asymmetry between 0.8-1.2 and >3000 plates / m. After packing the Capto™ MMC Impres material, the resulting chromatographic column was washed with 1M NAOH solution for 30 minutes and pre-equilibrated with a loading buffer solution having a pH of 4.5 and 300 mM NaCl (as an example, 24 mS / cm). The buffer solution contained a combination of salts such as sodium dihydrogen phosphate, TRIS, and glycine to obtain a pH of 4.5. The same solution was used to dissolve the lyophilized Adcetris® sample up to a concentration of 1 mg / ml.
[0142] The solution was loaded onto the prepared chromatographic column until a loading of 30 mg Adcetris® per ml resin was reached. These steps and subsequent steps were performed at a buffer velocity of @150 cm / h. After loading 30 mg / ml Adcetris®, the chromatographic column was washed with a buffer solution of pH 4.5 and then eluted using gradient elution with a buffer having a pH of 8.5 and 300 mM NaCl. The elution buffer was prepared using different salts such as sodium dihydrogen phosphate, TRIS, glycine, etc. The conductivity and pH values were traced during the experimental setup, which shows that Adcetris® elution from the column was achieved due to pH changes during gradient elution.
[0143] The sample eluate was fractionated and the fractions obtained were evaluated in line using two different methods for DAR species identification. The first method chosen was hydrophobic interaction chromatography using a mAbPac HIC-Butyl column with dimensions 4.6×100 mm from Thermo Fisher Scientific. Chromatographic separation of the fractionated sample enabled us to identify the different DAR species and their quality based on the different elution bands for each species (for example, DAR0 species eluted between 7-9 min, DAR2 species eluted between 10-14 min, DAR4 species eluted between 15-18 min and DAR6 species eluted between 19-22 min). An example chromatographic experiment with a 30 mg / ml Adcetris® load is shown in FIG. 15, where the UV adsorption signal trace is represented by a solid line and the pH signal trace is represented by a dashed line.
[0144] Analytical evaluation of the collected fractions using hydrophobic interaction chromatography is displayed in Figure 16, showing that the selected Capto™ MMC Impres resin was not able to bind all 30 mg of the ADC sample, and the separation was not efficient. The maximum purities obtained for the individual DAR species ranged from 52.92% for DAR2, 75.32% for DAR4, and 72.74% for DAR6. In comparison, the purities obtained on the innovative ion exchange resin under the same conditions were: DAR2 - 55.27%, DAR4 - 81.24%, and DAR6 - 86.89%. In addition, the recovery using the Capto MMC Impres resin was 88.38%.
[0145] 6. In this experiment, the separation matrix was evaluated for its ability to separate different DARs (drug-antibody ratios) of the ADC Adcetris®. For the following experiments, the resin was packed into a 5 mm diameter, 100 mm long column using a 20% ethanol, 150 mM NaCl solution. The following two buffers were prepared: loading buffer Buffer A (e.g., 0.00796 M citric acid, 0.009068 M sodium dihydrogen phosphate, 0.021543 M glycine, 0.010668 M TRIS, 0.007666 M succinate, 0.0111 M NaOH, and 0.0889 M NaCl, pH 4.75) and buffer B (e.g., 0.00796 M citric acid, 0.009068 M sodium dihydrogen phosphate, 0.021543 M glycine, 0.010668 M TRIS, 0.007666 M succinate, 0.046 M NaOH, and 0.054 M NaCl, pH 8.5).
[0146] The packed column was equilibrated at 0.491 ml / min with at least 10 column volumes of Buffer A. Lyophilized formulated ADC was dissolved in Buffer A to a concentration of 5 mg / ml. 3.93 ml of the resulting solution was loaded directly onto the equilibrated column at 0.491 ml / min. After loading, the column was washed with 10 CV using equilibration solution. Elution of bound ADC was performed using a pH gradient elution from 0-100% Buffer B at 0.491 ml / min in 120 CV (Figure 17).
[0147] Table 1. Analytical results of sample fraction characterization displayed as quantified area of elution fractions (peaks 1-3) encompassing 10 mg ADC / ml CV load and ADC loaded (load) at 50 mM NaCl. [Table 1]
[0148] 7. In this experiment, the separation matrix was evaluated for its ability to separate different DARs (drug-antibody ratios) of the ADC Adcetris®. For the following experiments, the resin was packed into a 5 mm diameter, 100 mm long column using a 20% ethanol, 150 mM NaCl solution. The following two buffers were prepared: loading buffer, buffer A (e.g., 0.00796 M citric acid, 0.009068 M sodium dihydrogen phosphate, 0.021543 M glycine, 0.010668 M TRIS, 0.007666 M succinate, 0.0111 M NaOH, and 0.1389 M NaCl, pH 4.75) and buffer B (e.g., 0.00796 M citric acid, 0.009068 M sodium dihydrogen phosphate, 0.021543 M glycine, 0.010668 M TRIS, 0.007666 M succinate, 0.046 M NaOH, and 0.104 M NaCl, pH 8.5).
[0149] The packed column was equilibrated at 0.491 ml / min with at least 10 column volumes of Buffer A. Lyophilized formulated ADC was dissolved in Buffer A to a concentration of 5 mg / ml. 3.93 ml of the resulting solution was loaded directly onto the equilibrated column at 0.491 ml / min. After loading, the column was washed with 10 CV using equilibration solution. Elution of bound ADC was performed using a pH gradient elution from 0-100% Buffer B at 0.491 ml / min in 120 CV (Figure 18).
[0150] Table 2. Analytical results of sample fraction characterization displayed as quantified area of elution fractions (peaks 1-3) encompassing 10 mg ADC / ml CV load and ADC loaded (load) at 100 mM NaCl. [Table 2]
[0151] 8. In this experiment, the separation matrix was evaluated for its ability to separate different DARs (drug-antibody ratios) of the ADC Adcetris®. For the following experiments, the resin was packed into a 5 mm diameter, 100 mm long column using a 20% ethanol, 150 mM NaCl solution. The following two buffers were prepared: loading buffer, buffer A (e.g., 0.00796 M citric acid, 0.009068 M sodium dihydrogen phosphate, 0.021543 M glycine, 0.010668 M TRIS, 0.007666 M succinate, 0.0111 M NaOH, and 0.1889 M NaCl, pH 4.75) and buffer B (e.g., 0.00796 M citric acid, 0.009068 M sodium dihydrogen phosphate, 0.021543 M glycine, 0.010668 M TRIS, 0.007666 M succinate, 0.046 M NaOH, and 0.154 M NaCl, pH 8.5).
[0152] The packed column was equilibrated at 0.491 ml / min with at least 10 column volumes of Buffer A. Lyophilized formulated ADC was dissolved in Buffer A to a concentration of 5 mg / ml. 3.93 ml of the resulting solution was loaded directly onto the equilibrated column at 0.491 ml / min. After loading, the column was washed with 10 CV using equilibration solution. Elution of bound ADC was performed using a pH gradient elution from 0-100% Buffer B at 0.491 ml / min in 120 CV (Figure 19).
[0153] Table 3. Analytical results of sample fraction characterization displayed as quantified area of elution fractions (peaks 1-3) encompassing 10 mg ADC / ml CV load and ADC loaded (load) at 150 mM NaCl. [Table 3]
[0154] 9. In this experiment, the separation matrix was evaluated for its ability to separate different DARs (drug-antibody ratios) of the ADC Adcetris®. For the following experiments, the resin was packed into a 5 mm diameter, 100 mm long column using a 20% ethanol, 150 mM NaCl solution. The following two buffers were prepared: loading buffer Buffer A (e.g., 0.00796 M citric acid, 0.009068 M sodium dihydrogen phosphate, 0.021543 M glycine, 0.010668 M TRIS, 0.007666 M succinate, 0.0111 M NaOH, and 0.2389 M NaCl, pH 4.75) and buffer B (e.g., 0.00796 M citric acid, 0.009068 M sodium dihydrogen phosphate, 0.021543 M glycine, 0.010668 M TRIS, 0.007666 M succinate, 0.046 M NaOH, and 0.204 M NaCl, pH 8.5).
[0155] The packed column was equilibrated at 0.491 ml / min with at least 10 column volumes of Buffer A. Lyophilized formulated ADC was dissolved in Buffer A to a concentration of 5 mg / ml. 3.93 ml of the resulting solution was loaded directly onto the equilibrated column at 0.491 ml / min. After loading, the column was washed with 10 CV using equilibration solution. Elution of bound ADC was performed using a pH gradient elution from 0-100% Buffer B at 0.491 ml / min in 120 CV (Figure 20).
[0156] Table 4. Analytical results of sample fraction characterization displayed as quantified area of elution fractions (peaks 1-3) encompassing 10 mg ADC / ml CV load and ADC loaded (load) at 200 mM NaCl. [Table 4]
[0157] 10. In this experiment, the separation matrix was evaluated for its ability to separate different DARs (drug-antibody ratios) of the ADC Adcetris®. For the following experiments, the resin was packed into a 5 mm diameter, 100 mm long column using a 20% ethanol, 150 mM NaCl solution. The following two buffers were prepared: loading buffer Buffer A (e.g., 0.00796 M citric acid, 0.009068 M sodium dihydrogen phosphate, 0.021543 M glycine, 0.010668 M TRIS, 0.007666 M succinate, 0.0111 M NaOH, and 0.3389 M NaCl, pH 4.75) and buffer B (e.g., 0.00796 M citric acid, 0.009068 M sodium dihydrogen phosphate, 0.021543 M glycine, 0.010668 M TRIS, 0.007666 M succinate, 0.046 M NaOH, and 0.304 M NaCl, pH 8.5).
[0158] The packed column was equilibrated at 0.491 ml / min with at least 10 column volumes of Buffer A. Lyophilized formulated ADC was dissolved in Buffer A to a concentration of 5 mg / ml. 3.93 ml of the resulting solution was loaded directly onto the equilibrated column at 0.491 ml / min. After loading, the column was washed with 10 CV using equilibration solution. Elution of bound ADC was performed using a pH gradient elution from 0-100% Buffer B at 0.491 ml / min in 120 CV (Figure 21).
[0159] Table 5. Analytical results of sample fraction characterization displayed as quantified area of elution fractions (peaks 1-3) encompassing 10 mg ADC / ml CV load and ADC loaded (load) at 300 mM NaCl. [Table 5]
[0160] 11. In this experiment, the separation matrix was evaluated for its ability to separate different DARs (drug-antibody ratios) of the ADC Adcetris®. For the following experiments, the resin was packed into a 5 mm diameter, 100 mm long column using a 20% ethanol, 150 mM NaCl solution. The following two buffers were prepared: loading buffer Buffer A (e.g., 0.00796 M citric acid, 0.009068 M sodium dihydrogen phosphate, 0.021543 M glycine, 0.010668 M TRIS, 0.007666 M succinate, 0.0111 M NaOH, and 0.3889 M NaCl, pH 4.75) and buffer B (e.g., 0.00796 M citric acid, 0.009068 M sodium dihydrogen phosphate, 0.021543 M glycine, 0.010668 M TRIS, 0.007666 M succinate, 0.046 M NaOH, and 0.354 M NaCl, pH 8.5).
[0161] The packed column was equilibrated at 0.491 ml / min with at least 10 column volumes of Buffer A. Lyophilized formulated ADC was dissolved in Buffer A to a concentration of 5 mg / ml. 3.93 ml of the resulting solution was loaded directly onto the equilibrated column at 0.491 ml / min. After loading, the column was washed with 10 CV using equilibration solution. Elution of bound ADC was performed using a pH gradient elution from 0-100% Buffer B at 0.491 ml / min in 120 CV (Figure 22).
[0162] Table 6. Analytical results of sample fraction characterization displayed as quantified area of elution fractions (peaks 1-3) encompassing 10 mg ADC / ml CV load and ADC loaded (load) at 350 mM NaCl. [Table 6]
[0163] 12. In this experiment, the separation matrix was evaluated for its ability to separate different DARs (drug-antibody ratios) of the ADC Adcetris®. For the following experiments, the resin was packed into a 5 mm diameter, 100 mm long column using a 20% ethanol, 150 mM NaCl solution. The following two buffers were prepared: loading buffer Buffer A (e.g., 0.00796 M citric acid, 0.009068 M sodium dihydrogen phosphate, 0.021543 M glycine, 0.010668 M TRIS, 0.007666 M succinate, 0.0111 M NaOH, and 0.3389 M NaCl, pH 4.75) and buffer B (e.g., 0.00796 M citric acid, 0.009068 M sodium dihydrogen phosphate, 0.021543 M glycine, 0.010668 M TRIS, 0.007666 M succinate, 0.046 M NaOH, and 0.304 M NaCl, pH 8.5).
[0164] The packed column was equilibrated at 0.491 ml / min with at least 10 column volumes of Buffer A. Lyophilized formulated ADC was dissolved in Buffer A to a concentration of 5 mg / ml. 3.93 ml of the resulting solution was loaded directly onto the equilibrated column at 0.491 ml / min. After loading, the column was washed with 10 CV using equilibration solution. Elution of bound ADC was performed using pH steps at 22% B, 30% B and 36% B at 0.491 ml / min (Figure 23).
[0165] Table 7. Analytical results of sample fraction characterization displayed as quantified area of elution fractions (steps 1-3) encompassing 10 mg ADC / ml CV load in step mode and ADC loaded at 300 mM NaCl (load). [Table 7]
[0166] 13. In this experiment, an innovative ion exchange material was evaluated for its ability to separate the ADC species of the commercial drug Kadcyla®. The ion exchange material was packed into a chromatographic column of dimensions 5 x 100 mm with an asymmetry between 0.8 and 1.2 and >3000 plates / m. After packing the ion exchange material, the resulting chromatographic column was washed with 1 M NAOH solution for 30 min, as well as pre-equilibrated with a loading buffer solution having a pH of 4.5 and 300 mM NaCl (as an example, 24 mS / cm). The buffer solution contained a combination of salts such as sodium dihydrogen phosphate, TRIS, glycine, etc., to obtain a pH of 4.5. The same solution was used to dissolve the lyophilized Kadcyla® sample up to a concentration of 1 mg / ml.
[0167] This solution was loaded onto the prepared chromatographic column until a loading of 30 mg Kadcyla® per ml resin was reached. These and subsequent steps were performed at a buffer velocity of @150 cm / h. After loading 30 mg / ml Kadcyla®, the chromatographic column was washed with a buffer solution of pH 4.5 and then eluted using gradient elution with a buffer having a pH of 8.5 and 300 mM NaCl. The elution buffer was prepared using different salts such as sodium dihydrogen phosphate, TRIS, glycine, etc. The conductivity and pH values were traced during the experimental setup, which shows that Kadcyla® elution from the column was achieved due to pH changes during gradient elution.
[0168] The sample eluate was fractionated and the resulting fractions were evaluated in line using two different methods for DAR species identification. The first method chosen was hydrophobic interaction chromatography using a mAbPac HIC-Butyl column with dimensions 4.6 x 100 mm from Thermo Fisher Scientific. Chromatographic separation of the fractionated sample enabled us to identify the different DAR species and their quality based on the different elution bands for each species.
[0169] The second method chosen was mass spectrometry, where different DAR species are separated based on their mass and ionization ratio. Using this method, qualitative, but not quantitative, sample evaluation is possible due to the different ionization of DAR species (e.g., higher DAR species tend to ionize to a lower extent). An example chromatographic experiment with 30 mg / ml Kadcyla® loading is shown in Figure 24, where the UV adsorption signal trace is represented by a solid line and the pH signal trace is represented by a dashed line.
[0170] Fractions were collected and analyzed using analytical HIC (hydrophobic interaction chromatography) HPLC, and the amounts of different DARs were calculated using the quantified areas. Figure 25 illustrates the separation of antibody drug conjugate species during a linear elution gradient on an analytical HPLC column.
[0171] Five successive elution pools were identified in the UV signal trace, representing five different antibody drug conjugate species: peak 1 represents an antibody drug conjugate species without drug, peak 2 represents an antibody drug conjugate species with one drug molecule conjugated to a single antibody molecule, peak 3 represents an antibody drug conjugate species with two drug molecules conjugated to a single antibody molecule, peak 4 represents an antibody drug conjugate species with three drug molecules conjugated to a single antibody molecule, and peak 5 represents an antibody drug conjugate species with >4 drug molecules conjugated to a single antibody molecule. The identified antibody drug conjugate species differ in their average hydrophobicity, with some being more hydrophilic (e.g., on the left) to hydrophobic (e.g., on the right).
[0172] Analytical evaluation using hydrophobic interaction chromatography of the collected fractions is displayed in FIG. 26 and shows that the selected innovative ion exchange resin was capable of separating the lower DAR species from the higher ones. Selected sample fractions were further evaluated using mass spectrometry to assess the quality of the DAR species separation. The results, shown in Figures 27-29, indicate that each of the resulting fractions contained the identified DAR species.
[0173] FIG. 27. Deconvoluted mass spectrum for a Kadcyla™ sample showing the distribution of DAR species ranging from DAR0 to DAR7 species. FIG. 28. Deconvoluted mass spectrum for a sample of elution fraction 3A4 showing the distribution of lower DAR species. FIG. 29. Deconvoluted mass spectrum for a sample of elution fraction 3B12 showing the distribution of higher DAR species.
[0174] 14. In this experiment, the separation matrix was evaluated for its ability to separate different DARs (drug antibody ratios) of the ADC Kadcyla®. For the following experiments, the resin was packed into a 5 mm diameter, 100 mm long column using a 20% ethanol, 150 mM NaCl solution. The following two buffers were prepared: loading buffer Buffer A (e.g., 0.00796 M citric acid, 0.009068 M sodium dihydrogen phosphate, 0.021543 M glycine, 0.010668 M TRIS, 0.007666 M succinate, 0.0111 M NaOH, and 0.2889 M NaCl, with a pH of 4.75 and a conductivity of approximately 28 mS / cm) and buffer B (e.g., 0.00796 M citric acid, 0.009068 M sodium dihydrogen phosphate, 0.021543 M glycine, 0.010668 M TRIS, 0.007666 M succinate, 0.046 M NaOH, and 0.254 M NaCl, with a pH of 8.5 and a conductivity of approximately 27 mS / cm).
[0175] The packed column was equilibrated at 0.491 ml / min with at least 10 column volumes of Buffer A. Lyophilized formulated ADC was dissolved in Buffer A to a concentration of 5 mg / ml. 22.52 ml of the resulting solution was loaded directly onto the equilibrated column at 0.491 ml / min. After loading, the column was washed with 10 CV using equilibration solution. Elution of bound ADC was performed using a pH gradient elution from 0-100% Buffer B at 0.491 ml / min in 120 CV (Figure 30). Using linear pH gradient elution, separation / enrichment at different DARs is possible, as shown in Figure 31. The purity of >DAR4 increased to 96% (starting level 68%).
[0176] 15. In this experiment, Capto™ MMC ImpRes chromatographic resin was evaluated for its ability to separate different DARs (drug-antibody ratios) of the ADC Kadcyla®. For the following experiments, the resin was packed in a 5 mm diameter, 100 mm long column using a 20% ethanol, 150 mM NaCl solution. The following two buffers were prepared: loading buffer Buffer A (e.g., 0.00796 M citric acid, 0.009068 M sodium dihydrogen phosphate, 0.021543 M glycine, 0.010668 M TRIS, 0.007666 M succinate, 0.0111 M NaOH, and 0.2889 M NaCl, with a pH of 4.75 and a conductivity of approximately 28 mS / cm) and buffer B (e.g., 0.00796 M citric acid, 0.009068 M sodium dihydrogen phosphate, 0.021543 M glycine, 0.010668 M TRIS, 0.007666 M succinate, 0.046 M NaOH, and 0.254 M NaCl, with a pH of 8.5 and a conductivity of approximately 27 mS / cm).
[0177] The packed column was equilibrated at 0.491 ml / min with at least 10 column volumes of Buffer A. Lyophilized formulated ADC was dissolved in Buffer A to a concentration of 5 mg / ml. 11.26 ml of the resulting solution was loaded directly onto the equilibrated column at 0.491 ml / min. After loading, the column was washed with 10 CV using equilibration solution. Elution of bound ADC was performed using a pH gradient elution from 0-100% Buffer B at 0.491 ml / min in 120 CV (Figure 32). Using linear pH gradient elution, separation / enrichment at different DARs is possible, as shown in Figure 32. The purity of >DAR4 was increased to >90% (starting level 72%).
[0178] 16. In this experiment, the separation matrix was evaluated for its ability to separate different DARs (drug antibody ratios) of the ADC Kadcyla®. For the following experiments, the resin was packed into a 5 mm diameter, 100 mm long column using a 20% ethanol, 150 mM NaCl solution. The following two buffers were prepared: loading buffer Buffer A (e.g., 0.00796 M citric acid, 0.009068 M sodium dihydrogen phosphate, 0.021543 M glycine, 0.010668 M TRIS, 0.007666 M succinate, 0.0111 M NaOH, and 0.4389 M NaCl, pH 4.75) and buffer B (e.g., 0.00796 M citric acid, 0.009068 M sodium dihydrogen phosphate, 0.021543 M glycine, 0.010668 M TRIS, 0.007666 M succinate, 0.046 M NaOH, and 0.404 M NaCl, pH 8.5).
[0179] The packed column was equilibrated at 0.491 ml / min with at least 10 column volumes of Buffer A. Lyophilized formulated ADC was dissolved in Buffer A to a concentration of 5 mg / ml. 3.93 ml of the resulting solution was loaded directly onto the equilibrated column at 0.491 ml / min. After loading, the column was washed with 10 CV using equilibration solution. Elution of bound ADC was performed using pH steps at 5% B and 40% B at 0.491 ml / min (Figure 34).
[0180] Table 8. Analytical results of sample fraction characterization displayed as quantified area of elution fractions (steps 1-2) encompassing 10 mg ADC / ml CV load in step mode and ADC loaded at 400 mM NaCl (load). [Table 8]
Claims
1. A separation material comprising a hydroxyl-containing base matrix having polymer chains covalently grafted to its surface, The polymer chain comprises an amino acid end group -N(Y)-R3, where a. Y are, independently of each other, H or CH3; and b. R3 is -CHCOOMR4; wherein R4 is C1-C4 alkyl or C1-C4 perfluoroalkyl; and M is H, Na, K, or NH 4 is The separation material.
2. 2. The separation material of claim 1, wherein the monomer units of the polymer chain are linearly linked and each monomer unit comprises an end group -N(Y)-R3.
3. The separation material according to claim 1 or 2, wherein the ion density is between 400 and 900 μeq / g.
4. The separation material according to any one of claims 1 to 3, wherein Y is H and R4 is isopropyl and / or isobutyl.
5. The separation material according to any one of claims 1 to 4, wherein the hydroxyl-containing base matrix comprises aliphatic hydroxyl groups.
6. 6. The separation material according to any one of claims 1 to 5, wherein the base matrix is formed by copolymerization of a hydrophilic substituted alkyl vinyl ether selected from the group of 1,4-butanediol monovinyl ether, 1,5-pentanediol monovinyl ether, diethylene glycol monovinyl ether or cyclohexanedimethanol monovinyl ether with divinylethyleneurea (1,3-divinylimidazolin-2-one) as a crosslinker.
7. The separation material according to any one of claims 1 to 6, wherein the hydroxyl-containing base matrix is a compound of formula V [Formula 1] wherein R1, R2 and Y are each independently H or CH3; R3 is -CHCOOMR4, wherein R4 is C1-C4 alkyl or C1-C4 perfluoroalkyl; and M is H, Na, K, or NH 4 That is, The separation material can be prepared by subjecting a monomer according to the formula (I) to cerium (IV) catalyzed graft polymerization.
8. 1. A process for the chromatographic purification and / or separation of antibody drug conjugates (ADCs) by contacting a sample containing the ADCs with a separation material comprising a hydroxyl-containing base matrix having polymer chains covalently grafted to its surface, the process comprising: the polymer comprises an end group -N(Y)-R3; wherein each Y is independently H or CH3; R3 is -CHCOOMR4, wherein R4 is C1-C4 alkyl or C1-C4 perfluoroalkyl; and M is H, Na, K, or NH 4 is The process,
9. The process of claim 8, wherein the ADC target molecule binds to the separation matrix at a pH between 2 and 7.
10. A process according to claim 8 or 9, wherein the sample is applied to the separation matrix at an ion density between 10 and 1200 μeq / g.
11. 11. The process of any one of claims 8 to 10, wherein between 10 mg and 100 mg of ADC are bound per ml of separated material.
12. A process for the preparation of a separation material according to any one of claims 1 to 7, comprising treating a hydroxyl-containing base matrix with a compound of formula V [chemical 2] wherein R1, R2 and Y are each independently H or CH3; R3 is -CHCOOMR4, where R4 is C1-C4 alkyl or C1-C4 perfluoroalkyl, and M is H, Na, K, or NH 4 That is, by subjecting the monomer to a cerium(IV) catalyzed graft polymerization according to
Citation Information
Patent Citations
Graft copolymers for cation exchange chromatography
JP2010528271A
Purification of immunoglobulin from plasma
JP2016041688A
A method for controlling the levels of high-mannose glycoforms using ion-exchange chromatography
JP2016504337A
Purification of antibody-drug conjugates (adc)
JP2016519070A
